Shamburg News · 8-K filed Nov 12, 2026, 7:07 AM EST

Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Business Update

YARW · Yarrow Bioscience, Inc.

  • Earnings
  • Financing
  • Materiality: high

Yarrow Bioscience, Inc. reported financial results for the quarter ended September 30, 2026, in a press release furnished under Item 2.02. The company reported cash and cash equivalents of $268.9 million as of September 30, 2026, and a net loss of $9.7 million for the third quarter, with R&D expenses of $5.3 million and G&A expenses of $5.5 million. The release also described completion of an underwritten public offering with approximately $172.5 million in gross proceeds and enrollment ongoing in the Phase 2a/2b DIRECTION-GD trial of YB-101.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001566044-26-000017.

Written from the filing by Shamburg Markets. Figures are as reported by the company.